Skip to main content

HLA DRA Antibody (CL10964)

Novus Biologicals, part of Bio-Techne | Catalog # NBP3-07996

Novus Biologicals, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
NBP3-07996-100ul
NBP3-07996-25ul

Key Product Details

Validated by

Orthogonal Validation

Species Reactivity

Validated:

Human

Applications

Immunohistochemistry, Immunohistochemistry-Paraffin, Western Blot

Label

Unconjugated

Antibody Source

Monoclonal Mouse IgG1 Clone # CL10964

Concentration

Concentrations vary lot to lot. See vial label for concentration. If unlisted please contact technical services.

Product Summary for HLA DRA Antibody (CL10964)

Immunogen

This antibody was developed against a synthetic peptide corresponding to amino acids: EFYLNPDQSGEFMFDFDGDE

Clonality

Monoclonal

Host

Mouse

Isotype

IgG1

Scientific Data Images for HLA DRA Antibody (CL10964)

Western Blot: HLA DRA Antibody (CL10964) [NBP3-07996]

Western Blot: HLA DRA Antibody (CL10964) [NBP3-07996]

Western Blot: HLA DRA Antibody (CL10961) [NBP3-07996] - Analysis in human cell line Daudi.
Immunohistochemistry-Paraffin: HLA DRA Antibody (CL10964) [NBP3-07996]

Immunohistochemistry-Paraffin: HLA DRA Antibody (CL10964) [NBP3-07996]

Immunohistochemistry-Paraffin: HLA DRA Antibody (CL10961) [NBP3-07996] - Staining of human tonsil shows strong membranous positivity in germinal center cells.
Immunohistochemistry-Paraffin: HLA DRA Antibody (CL10964) [NBP3-07996]

Immunohistochemistry-Paraffin: HLA DRA Antibody (CL10964) [NBP3-07996]

Immunohistochemistry-Paraffin: HLA DRA Antibody (CL10961) [NBP3-07996] - Analysis in human tonsil and testis tissues using NBP3-07996 antibody. Corresponding HLA DRA RNA-seq data are presented for the same tissues.

Applications for HLA DRA Antibody (CL10964)

Application
Recommended Usage

Immunohistochemistry

1:50 - 1:200

Immunohistochemistry-Paraffin

1:50 - 1:200

Western Blot

1 ug/ml
Application Notes
For IHC-Paraffin, HIER pH 6 retrieval is recommended.
Please Note: Optimal dilutions of this antibody should be experimentally determined.

Formulation, Preparation, and Storage

Purification

Protein A purified

Formulation

PBS, pH 7.2, containing 40% glycerol

Preservative

0.02% Sodium Azide

Concentration

Concentrations vary lot to lot. See vial label for concentration. If unlisted please contact technical services.

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.

Background: HLA DRA

HLA-DRA is one of the HLA class II alpha chain paralogues. This class II molecule is a heterodimer consisting of an alpha and a beta chain, both anchored in the membrane. It plays a central role in the immune system by presenting peptides derived from extracellular proteins. Class II molecules are expressed in antigen presenting cells (APC: B lymphocytes, dendritic cells, macrophages). The alpha chain is approximately 33-35 kDa and its gene contains 5 exons. Exon 1 encodes the leader peptide, exons 2 and 3 encode the two extracellular domains, and exon 4 encodes the transmembrane domain and the cytoplasmic tail. DRA does not have polymorphisms in the peptide binding part and acts as the sole alpha chain for DRB1, DRB3, DRB4 and DRB5.

Alternate Names

FLJ51114, histocompatibility antigen HLA-DR alpha, HLA class II histocompatibility antigen, DR alpha chain, HLA-DRA1, major histocompatibility complex, class II, DR alpha, MHC cell surface glycoprotein, MHC class II antigen DRA, MLRW

Gene Symbol

HLA-DRA

Additional HLA DRA Products

Product Documents for HLA DRA Antibody (CL10964)

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Product Specific Notices for HLA DRA Antibody (CL10964)

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Loading...
Loading...
Loading...
Loading...